CN101969983B - 治疗和/或预防早产并发症的方法和产品 - Google Patents

治疗和/或预防早产并发症的方法和产品 Download PDF

Info

Publication number
CN101969983B
CN101969983B CN200880012284.9A CN200880012284A CN101969983B CN 101969983 B CN101969983 B CN 101969983B CN 200880012284 A CN200880012284 A CN 200880012284A CN 101969983 B CN101969983 B CN 101969983B
Authority
CN
China
Prior art keywords
igfbp
igf
insulin
growth factor
rop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880012284.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101969983A (zh
Inventor
安·赫尔斯特罗姆
切特里纳·洛夫克维斯特
罗耶斯·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Human Genetics Therapies Inc
Original Assignee
Premacure AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Premacure AB filed Critical Premacure AB
Publication of CN101969983A publication Critical patent/CN101969983A/zh
Application granted granted Critical
Publication of CN101969983B publication Critical patent/CN101969983B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880012284.9A 2007-04-18 2008-04-18 治疗和/或预防早产并发症的方法和产品 Active CN101969983B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92396307P 2007-04-18 2007-04-18
US60/923,963 2007-04-18
PCT/SE2008/050441 WO2008130315A1 (en) 2007-04-18 2008-04-18 Method and product for treatment and/or prevention of complications of prematurity

Publications (2)

Publication Number Publication Date
CN101969983A CN101969983A (zh) 2011-02-09
CN101969983B true CN101969983B (zh) 2014-11-05

Family

ID=39875739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012284.9A Active CN101969983B (zh) 2007-04-18 2008-04-18 治疗和/或预防早产并发症的方法和产品

Country Status (5)

Country Link
US (3) US8518877B2 (https=)
EP (1) EP2148695B1 (https=)
JP (2) JP5449134B2 (https=)
CN (1) CN101969983B (https=)
WO (1) WO2008130315A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity
JP6284341B2 (ja) 2012-10-24 2018-02-28 国立大学法人東京農工大学 未熟児網膜症の治療又は予防剤、未熟児網膜症の検査方法及び未熟児網膜症の治療又は予防物質のスクリーニング方法
US9510055B2 (en) 2013-01-23 2016-11-29 Sonos, Inc. System and method for a media experience social interface
US20150220498A1 (en) 2014-02-05 2015-08-06 Sonos, Inc. Remote Creation of a Playback Queue for a Future Event
US9679054B2 (en) 2014-03-05 2017-06-13 Sonos, Inc. Webpage media playback
US20150324552A1 (en) 2014-05-12 2015-11-12 Sonos, Inc. Share Restriction for Media Items
US20150356084A1 (en) 2014-06-05 2015-12-10 Sonos, Inc. Social Queue
US9874997B2 (en) 2014-08-08 2018-01-23 Sonos, Inc. Social playback queues
EP3114852A1 (en) 2014-09-24 2017-01-11 Sonos Inc. Social media queue
WO2016049342A1 (en) 2014-09-24 2016-03-31 Sonos, Inc. Social media connection recommendations based on playback information
US9959087B2 (en) 2014-09-24 2018-05-01 Sonos, Inc. Media item context from social media
US10645130B2 (en) 2014-09-24 2020-05-05 Sonos, Inc. Playback updates
US9690540B2 (en) 2014-09-24 2017-06-27 Sonos, Inc. Social media queue
US9860286B2 (en) 2014-09-24 2018-01-02 Sonos, Inc. Associating a captured image with a media item
US9667679B2 (en) 2014-09-24 2017-05-30 Sonos, Inc. Indicating an association between a social-media account and a media playback system
US9723038B2 (en) 2014-09-24 2017-08-01 Sonos, Inc. Social media connection recommendations based on playback information
WO2018093797A1 (en) * 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP4663184A3 (en) * 2017-09-11 2026-03-18 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN114126640B (zh) * 2019-05-28 2024-10-29 爱儿安制药有限公司 治疗视网膜病变的组合物和方法
WO2023242442A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
EP4598630A1 (en) * 2022-10-04 2025-08-13 Oak Hill Bio Limited Method of treating neonates with igf-1 complex
WO2024160999A1 (en) * 2023-02-03 2024-08-08 Oak Hill Bio Limited Treatment of kidney injury with igf-1 complex
WO2024170612A1 (en) * 2023-02-14 2024-08-22 Oak Hill Bio Limited Treatment of healing dysregulation in gi tissue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387440A (zh) * 1999-06-04 2002-12-25 谢尔特里克斯药品公司 治疗糖尿病的方法
WO2007011926A2 (en) * 2005-07-15 2007-01-25 Children's Medical Center Corporation Methods for treating and diagnosing complications of premature birth

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
JPH07508025A (ja) * 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子（ｉｇｆ−１）類似体
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60143858D1 (de) 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1387440A (zh) * 1999-06-04 2002-12-25 谢尔特里克斯药品公司 治疗糖尿病的方法
WO2007011926A2 (en) * 2005-07-15 2007-01-25 Children's Medical Center Corporation Methods for treating and diagnosing complications of premature birth

Also Published As

Publication number Publication date
JP2013249317A (ja) 2013-12-12
US9463222B2 (en) 2016-10-11
EP2148695A1 (en) 2010-02-03
EP2148695B1 (en) 2014-10-15
JP2010524928A (ja) 2010-07-22
US8518877B2 (en) 2013-08-27
EP2148695A4 (en) 2013-01-16
JP5449134B2 (ja) 2014-03-19
CN101969983A (zh) 2011-02-09
WO2008130315A1 (en) 2008-10-30
US20130310316A1 (en) 2013-11-21
US20100204101A1 (en) 2010-08-12
US20150216943A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CN101969983B (zh) 治疗和/或预防早产并发症的方法和产品
Johnston et al. Insulin-like growth factor-1 is a potent neuronal rescue agent after hypoxic-ischemic injury in fetal lambs.
RU2733464C2 (ru) Препараты tpp1 и способы лечения заболевания cln2
US8852936B2 (en) Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
ES2751391T3 (es) Procedimientos de tratamiento de trastornos metabólicos
CA2398030A1 (en) Therapeutic agents for achondroplasia
Tracy et al. Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis
JPWO2018186480A1 (ja) 線維性疾患の治療薬
CA2689549A1 (en) Igf for the treatment of rett syndrome and synaptic disorders
JPH09509140A (ja) 神経学的障害の治療方法
WO2018031922A1 (en) Medical and nutritional compositions and methods of use
Li et al. Intranasal oxytocin restores maternal behavior and oxytocin neuronal activity in the supraoptic nucleus in rat dams with cesarean delivery
JP2022546856A (ja) 歯周組織由来の多分化能幹細胞を含む肥満または非アルコール性脂肪肝の予防または治療用薬学的組成物
EP3621634A1 (en) Compositions and methods for treating idiopathic overactive bladder syndrome and detrusor overactivity
US20240189395A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
US11931403B2 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
CN118831152A (zh) 导管素抗菌肽在缺血性脑卒中药物中的应用
Andre Exploring Fibrosis in Muscular Dystrophy through Modulation of the TGF-Beta Pathway
WO2025179292A1 (en) Compositions, systems, and methods for treating or reducing hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates
UA145507U (uk) Спосіб комбінованого лікування цукрового діабету 2 типу та його ускладнень
TW201822775A (zh) 用於治療坐骨神經損傷之醫藥組合物
Smith Can we restore aspects of the in utero environment in premature infants to prevent disease?
JP2023167026A (ja) 膵機能活性化剤、抗老化剤、２型糖尿病の治療薬または予防薬、医薬品、化粧品および食品または飲料
CN120570997A (zh) Foxn3在制备预防或治疗肥胖药物的应用
Goth et al. P03-37 Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: A phase II, dose and frequency finding study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220117

Address after: Delaware

Patentee after: SHIRE HUMAN GENETIC THERAPIES, Inc.

Address before: Uppsala, Sweden

Patentee before: Premacure AB